REVB
Price
$3.83
Change
+$0.15 (+4.08%)
Updated
Oct 23 closing price
Capitalization
15.26M
13 days until earnings call
Intraday BUY SELL Signals
SABS
Price
$2.84
Change
-$0.20 (-6.58%)
Updated
Oct 23 closing price
Capitalization
258.4M
21 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

REVB vs SABS

REVB vs SABS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
REVB vs. SABS commentary
Oct 24, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REVB is a Hold and SABS is a Buy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for REVB with price predictions
Oct 22, 2026

REVB in -40.51% downward trend, sliding for three consecutive days on October 19, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where REVB declined for three days, in 348 of 369 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for REVB entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where REVB's RSI Indicator exited the oversold zone, 45 of 48 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 20 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

REVB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 1 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 67 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.515) is normal, around the industry mean (2.973). P/E Ratio (0.142) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. REVB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REVB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for SABS with price predictions
Oct 22, 2026

SABS's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for SABS turned positive on October 21, 2026. Looking at past instances where SABS's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SABS's RSI Oscillator exited the oversold zone, 26 of 31 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.

The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on SABS as a result. In 74 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.

Following a +13.83% 3-day Advance, the price is estimated to grow further. Considering data from situations where SABS advanced for three days, in 168 of 212 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

SABS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SABS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for SABS entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 73 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.203) is normal, around the industry mean (2.973). P/E Ratio (2.272) is within average values for comparable stocks, (-1.705). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (128.121) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).

The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. SABS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SABS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

FUNDAMENTALS RATINGS
REVB: Fundamental Ratings
REVB
OUTLOOK RATING
1..100
80
VALUATION
overvalued / fair valued / undervalued
1..100
67
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
94
P/E GROWTH RATING
1..100
1
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
REVBSABS
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
N/A
Bullish Trend 2 days ago
75%
MACD
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
79%
Declines
ODDS (%)
Bearish Trend 5 days ago
90%
Bearish Trend 10 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
83%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Oct 24, 2026
Stock price -- (REVB: $3.68 vs. SABS: $3.04)
Brand notoriety: REVB and SABS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REVB: 333% vs. SABS: 126%
Market capitalization -- REVB: $15.26M vs. SABS: $258.4M
REVB [@Biotechnology] is valued at $15.26M. SABS’s [@Biotechnology] market capitalization is $258.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $132.8B. The average market capitalization across the [@Biotechnology] industry is $2.14B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REVB’s FA Score shows that 1 FA rating(s) are green while SABS’s FA Score has 0 green FA rating(s).

  • REVB’s FA Score: 1 green, 4 red.
  • SABS’s FA Score: 0 green, 5 red.
According to our system of comparison, REVB is a better buy in the long-term than SABS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REVB’s TA Score shows that 3 TA indicator(s) are bullish while SABS’s TA Score has 5 bullish TA indicator(s).

  • REVB’s TA Score: 3 bullish, 2 bearish.
  • SABS’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, SABS is a better buy in the short-term than REVB.

Price Growth

REVB (@Biotechnology) experienced а -30.96% price change this week, while SABS (@Biotechnology) price change was +17.37% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.28%. For the same industry, the average monthly price growth was -16.27%, and the average quarterly price growth was -16.72%.

Reported Earning Dates

REVB is expected to report earnings on Nov 05, 2026.

SABS is expected to report earnings on Nov 13, 2026.

Industries' Descriptions

@Biotechnology (+1.28% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
REVB
Daily Signal:
Gain/Loss:
SABS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement

SABS and

Correlation & Price change

A.I.dvisor indicates that over the last year, SABS has been loosely correlated with REVB. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SABS jumps, then REVB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SABS
1D Price
Change %
SABS100%
+7.80%
REVB - SABS
48%
Loosely correlated
+1.38%
INKT - SABS
47%
Loosely correlated
-5.27%
CYPH - SABS
46%
Loosely correlated
-10.51%
VYGR - SABS
38%
Loosely correlated
-7.92%
WHWK - SABS
36%
Loosely correlated
-1.07%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
WCBR47.120.53
+1.14%
WisdomTree Cybersecurity Fund (WCBR)
IBTL19.690.14
+0.72%
iShares iBonds Dec 2031 Term Treasury ETF (IBTL)
YBIT20.02-0.62
-3.03%
Yieldmax Bitcoin Option Income Strategy ETF
BOEG9.39-0.49
-4.92%
Leverage Shares 2X Long BA Daily ETF (BOEG)
PSLV17.64-1.05
-5.62%
Sprott Physical Silver Trust